Plant Name: Adiantum lunulatum
Taxonomic Information:
Plant ID: NPO17169
Plant Latin Name: Adiantum lunulatum
Taxonomy Genus: Adiantum
Taxonomy Family: Pteridaceae
Plant External Links:
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
China; IndiaTraditional Medicine System:
Indian Folk; TCM; AyurvedaGeographical Distribution:
India; China
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| NPSR1; | |
| ALPL; RECQL; TDP1; PIK3CA; PIK3CB; GLO1; PGD; ALOX12; GFER; HSD17B10; NQO2; NOX4; APEX1; POLB; | |
| ACHE; | |
| CDC25B; | |
| BCL2; | |
| TOP2A; | |
| MET; AXL; FLT3; CDK1; PIM1; KDR; IGF1R; AURKB; | |
| CA2; CA12; CA9; CA14; CA7; CA4; | |
| ESR1; | |
| NR1H4; | |
| PTGS2; PTGS1; | |
| NFKB1; | |
| SLCO1B1; | |
| LMNA; | |
| L3MBTL1; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | PGD | 6-phosphogluconate dehydrogenase | P52209 | CHEMBL3404 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | NQO2 | Quinone reductase 2 | P16083 | CHEMBL3959 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | PIK3CA | PI3-kinase p110-alpha subunit | P42336 | CHEMBL4005 |
| Enzyme_unclassified | PIK3CB | PI3-kinase p110-beta subunit | P42338 | CHEMBL3145 |
| Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Isomerase | TOP2A | DNA topoisomerase II alpha | P11388 | CHEMBL1806 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
| Miscellaneous ion channel | BCL2 | Apoptosis regulator Bcl-2 | P10415 | CHEMBL4860 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 5.568E-13 | 6.062E-09 | CA12, CA14, CA2, CA4, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 7.468E-10 | 1.355E-06 | CA12, CA14, CA2, CA4, CA7, CA9 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.751E-08 | 1.412E-05 | CYP1A1, CYP1A2, CYP1B1, CYP3A4, NOX4, PTGS1, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.949E-08 | 1.516E-05 | CA12, CA2, CA4, CA7, CA9 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 6.220E-08 | 3.508E-05 | CYP1A1, CYP1A2, CYP1B1, CYP3A4, NOX4 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 9.710E-08 | 4.917E-05 | ALPL, APEX1, CYP1A1, CYP1B1, ESR1, FLT3, NFKB1, NOX4, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.203E-07 | 9.790E-05 | CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0006954; inflammatory response | 5.924E-07 | 2.224E-04 | AXL, NFKB1, NOX4, NR1H4, PIK3CA, PIK3CB, POLB, PTGS1, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.402E-06 | 4.146E-04 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0043560; insulin receptor substrate binding | 1.924E-06 | 5.110E-04 | IGF1R, PIK3CA, PIK3CB |
| BP | GO:0050896; response to stimulus | GO:0032496; response to lipopolysaccharide | 3.292E-06 | 7.966E-04 | ALPL, AXL, CYP1A1, CYP1A2, NFKB1, NR1H4, PTGS2 |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 5.307E-06 | 1.204E-03 | APEX1, POLB |
| MF | GO:0003824; catalytic activity | GO:0004666; prostaglandin-endoperoxide synthase activity | 5.307E-06 | 1.204E-03 | PTGS1, PTGS2 |
| BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 1.217E-05 | 2.500E-03 | APEX1, AXL, CDK1, CYP1B1 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.379E-05 | 2.781E-03 | CA12, CA2, CA4, CA7, CA9, ESR1, GLO1, L3MBTL1, NQO2, NR1H4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.526E-05 | 3.010E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.590E-05 | 3.010E-03 | CA2, CA7 |
| BP | GO:0019740; nitrogen utilization | GO:0006808; regulation of nitrogen utilization | 1.590E-05 | 3.010E-03 | BCL2, NR1H4 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 1.590E-05 | 3.010E-03 | CYP1A1, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0055082; cellular chemical homeostasis | 1.646E-05 | 3.063E-03 | BCL2, CA2, CA7, ESR1, NOX4, NPSR1, NR1H4, PIK3CA, PIK3CB |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 2.025E-05 | 3.615E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 2.355E-05 | 4.038E-03 | AXL, KDR, PIK3CA, PIK3CB |
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 2.678E-05 | 4.417E-03 | AXL, MET, NOX4, PIK3CA, PIK3CB |
| BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 2.921E-05 | 4.711E-03 | ALOX12, BCL2, CDC25B, CDK1, ESR1, FLT3, IGF1R, KDR, PIM1, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 3.175E-05 | 4.952E-03 | CYP1A1, CYP1A2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 3.175E-05 | 4.952E-03 | CYP1A2, CYP3A4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.424E-05 | 5.251E-03 | ALOX12, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0008610; lipid biosynthetic process | 3.634E-05 | 5.534E-03 | ACHE, ALOX12, CYP1A1, CYP3A4, PIK3CA, PIK3CB, PTGS1, PTGS2 |
| CC | GO:0016020; membrane | GO:0005886; plasma membrane | 3.986E-05 | 6.027E-03 | ACHE, ALOX12, ALPL, AXL, CA12, CA14, CA2, CA4, CA9, ESR1, FLT3, GLO1, HSD17B10, IGF1R, KDR, L3MBTL1, MET, NPSR1, PIK3CA, PIK3CB, PIM1, SLCO1B1, TDP1 |
| MF | GO:0005488; binding | GO:0000166; nucleotide binding | 4.853E-05 | 7.084E-03 | AURKB, AXL, CDK1, FLT3, GFER, IGF1R, KDR, MET, NOX4, NQO2, PIK3CA, PIK3CB, PIM1, RECQL, TOP2A |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 5.283E-05 | 7.471E-03 | CYP1A1, CYP3A4 |
| BP | GO:0040011; locomotion | GO:0030335; positive regulation of cell migration | 6.704E-05 | 9.181E-03 | ALOX12, BCL2, IGF1R, KDR, MET, NOX4, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0018108; peptidyl-tyrosine phosphorylation | 7.013E-05 | 9.369E-03 | AXL, FLT3, IGF1R, KDR, MET |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.114E-12 | 1.560E-10 | CA12, CA2, CA4, CA7, CA9, CA14 |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 1.760E-07 | 1.232E-05 | PIK3CA, FLT3, PIM1, PIK3CB, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 2.880E-07 | 1.344E-05 | PIK3CA, PIM1, BCL2, CYP1B1, PTGS2, MET, NFKB1, CDC25B |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 2.547E-06 | 4.665E-05 | PIK3CA, FLT3, BCL2, PIK3CB, PTGS2, MET, NFKB1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 1.654E-06 | 3.859E-05 | PIK3CA, BCL2, PIK3CB, NFKB1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05222 | Small cell lung cancer | 1.395E-06 | 3.859E-05 | PIK3CA, BCL2, PIK3CB, PTGS2, NFKB1 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 3.094E-06 | 4.771E-05 | PIK3CA, PIM1, BCL2, PIK3CB, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04914 | Progesterone-mediated oocyte maturation | 2.666E-06 | 4.665E-05 | PIK3CA, CDK1, PIK3CB, CDC25B, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.100E-06 | 3.850E-05 | CYP1A2, CYP1A1, CYP1B1, CYP3A4, PTGS2 |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 5.948E-06 | 6.405E-05 | PIK3CA, KDR, PIK3CB, ESR1, MET, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 3.408E-06 | 4.771E-05 | PIK3CA, BCL2, PIK3CB, NFKB1, IGF1R |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 5.782E-06 | 6.405E-05 | PIK3CA, KDR, BCL2, PIK3CB, MET, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 1.024E-05 | 8.750E-05 | PIK3CA, KDR, BCL2, PIK3CB, MET, NFKB1, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 4.774E-06 | 6.076E-05 | CYP1A1, CYP1B1, PTGS2, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 1.126E-05 | 8.757E-05 | PIK3CA, KDR, PIK3CB, MET, NFKB1, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 7.540E-06 | 7.540E-05 | PIK3CA, PIK3CB, PTGS2, PTGS1 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 1.526E-05 | 1.082E-04 | PIK3CA, LMNA, BCL2, PIK3CB, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04370 | VEGF signaling pathway | 1.063E-05 | 8.750E-05 | PIK3CA, KDR, PIK3CB, PTGS2 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 8.681E-06 | 8.102E-05 | CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 1.545E-05 | 1.082E-04 | PIK3CA, FLT3, PIK3CB, MET |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 1.946E-05 | 1.238E-04 | PIK3CA, PIK3CB, MET, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 2.057E-05 | 1.252E-04 | PIK3CA, PIK3CB, ESR1, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05169 | Epstein-Barr virus infection | 8.800E-05 | 4.739E-04 | PIK3CA, BCL2, CDK1, PIK3CB, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 9.433E-05 | 4.891E-04 | POLB, PIK3CA, CDK1, PIK3CB, NFKB1 |
| 09150 Organismal Systems | 09149 Aging | hsa04211 | Longevity regulating pathway - mammal | 5.882E-05 | 3.294E-04 | PIK3CA, PIK3CB, NFKB1, IGF1R |
| 09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 1.946E-05 | 1.238E-04 | SLCO1B1, CA2, NR1H4, CYP3A4 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 1.080E-04 | 5.062E-04 | PIK3CA, KDR, PIK3CB, MET, IGF1R |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 2.173E-05 | 1.268E-04 | CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04725 | Cholinergic synapse | 1.124E-04 | 5.074E-04 | ACHE, PIK3CA, BCL2, PIK3CB |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04668 | TNF signaling pathway | 1.085E-04 | 5.062E-04 | PIK3CA, PIK3CB, PTGS2, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05145 | Toxoplasmosis | 1.423E-04 | 6.226E-04 | PIK3CA, BCL2, PIK3CB, NFKB1 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04722 | Neurotrophin signaling pathway | 1.518E-04 | 6.253E-04 | PIK3CA, BCL2, PIK3CB, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 3.218E-04 | 1.287E-03 | PIK3CA, BCL2, PIK3CB, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 1.518E-04 | 6.253E-04 | PIK3CA, BCL2, PIK3CB, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04630 | Jak-STAT signaling pathway | 4.341E-04 | 1.436E-03 | PIK3CA, PIM1, BCL2, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 7.088E-04 | 2.144E-03 | FLT3, MET, NFKB1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05210 | Colorectal cancer | 3.669E-04 | 1.388E-03 | PIK3CA, BCL2, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 4.217E-04 | 1.436E-03 | PIK3CA, PIK3CB, IGF1R |
| 09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 4.029E-04 | 1.436E-03 | PIK3CA, PIK3CB, IGF1R |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 1.525E-03 | 4.027E-03 | CYP1A2, CYP1A1, ALPL, ALOX12, PTGS2, PGD, CYP3A4, HSD17B10, PTGS1 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 9.921E-05 | 4.961E-04 | CYP1A2, CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 5.930E-04 | 1.845E-03 | PIK3CA, PIK3CB, NFKB1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 3.669E-04 | 1.388E-03 | ALOX12, PTGS2, PTGS1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04662 | B cell receptor signaling pathway | 5.930E-04 | 1.845E-03 | PIK3CA, PIK3CB, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 4.411E-04 | 1.436E-03 | PIK3CA, PIK3CB, NFKB1 |
| 09150 Organismal Systems | 09157 Sensory system | hsa04750 | Inflammatory mediator regulation of TRP channels | 1.394E-03 | 3.904E-03 | PIK3CA, ALOX12, PIK3CB |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 4.217E-04 | 1.436E-03 | CYP1A2, CYP1A1, CYP3A4 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 1.436E-03 | 3.941E-03 | PIK3CA, PIK3CB, ESR1 |
| 09160 Human Diseases | 09161 Cancers | hsa05211 | Renal cell carcinoma | 4.411E-04 | 1.436E-03 | PIK3CA, PIK3CB, MET |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04064 | NF-kappa B signaling pathway | 1.199E-03 | 3.472E-03 | BCL2, PTGS2, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05146 | Amoebiasis | 1.478E-03 | 3.979E-03 | PIK3CA, PIK3CB, NFKB1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04660 | T cell receptor signaling pathway | 1.654E-03 | 4.210E-03 | PIK3CA, PIK3CB, NFKB1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04620 | Toll-like receptor signaling pathway | 1.747E-03 | 4.367E-03 | PIK3CA, PIK3CB, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05100 | Bacterial invasion of epithelial cells | 7.197E-04 | 2.144E-03 | PIK3CA, PIK3CB, MET |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04931 | Insulin resistance | 1.892E-03 | 4.647E-03 | PIK3CA, PIK3CB, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05166 | HTLV-I infection | 2.661E-03 | 5.914E-03 | POLB, PIK3CA, PIK3CB, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05142 | Chagas disease (American trypanosomiasis) | 1.654E-03 | 4.210E-03 | PIK3CA, PIK3CB, NFKB1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04611 | Platelet activation | 2.607E-03 | 5.887E-03 | PIK3CA, PIK3CB, PTGS1 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 2.044E-03 | 4.851E-03 | ALOX12, PTGS2, PTGS1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 2.372E-03 | 5.534E-03 | PIK3CA, PIK3CB, ESR1 |
| 09150 Organismal Systems | 09158 Development | hsa04380 | Osteoclast differentiation | 3.257E-03 | 6.952E-03 | PIK3CA, PIK3CB, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04152 | AMPK signaling pathway | 2.730E-03 | 5.972E-03 | PIK3CA, PIK3CB, IGF1R |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 3.327E-03 | 6.952E-03 | PIK3CA, PIK3CB, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04068 | FoxO signaling pathway | 3.327E-03 | 6.952E-03 | PIK3CA, PIK3CB, IGF1R |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05162 | Measles | 3.542E-03 | 7.187E-03 | PIK3CA, PIK3CB, NFKB1 |
| 09150 Organismal Systems | 09153 Circulatory system | hsa04261 | Adrenergic signaling in cardiomyocytes | 4.488E-03 | 8.851E-03 | PIK3CA, BCL2, PIK3CB |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 3.998E-03 | 7.997E-03 | PIK3CA, PIK3CB, IGF1R |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04932 | Non-alcoholic fatty liver disease (NAFLD) | 4.747E-03 | 9.103E-03 | PIK3CA, PIK3CB, NFKB1 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04930 | Type II diabetes mellitus | 5.228E-03 | 9.892E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09154 Digestive system | hsa04973 | Carbohydrate digestion and absorption | 4.608E-03 | 8.961E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09155 Excretory system | hsa04960 | Aldosterone-regulated sodium reabsorption | 3.479E-03 | 7.163E-03 | PIK3CA, PIK3CB |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.934E-03 | 4.667E-03 | CYP1A2, CYP3A4 |
| 09120 Genetic Information Processing | 09124 Replication and repair | hsa03410 | Base excision repair | 2.500E-03 | 5.738E-03 | POLB, APEX1 |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 1.215E-03 | 3.472E-03 | CA2, CA4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1; CDK1; IGF1R; ACHE; PTGS1; PTGS2; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; BCL2; |
| C00-D49: Neoplasms | Prostate cancer | C61 | ESR1; FLT3; BCL2; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; |
| C00-D49: Neoplasms | Breast cancer | C50 | ESR1; CDK1; IGF1R; KDR; FLT3; NQO2; CA9; BCL2; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; NPSR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; PTGS2; |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | TOP2A; MET; AURKB; IGF1R; PIK3CA; KDR; FLT3; PIK3CB; CA9; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS1; PTGS2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1; PTGS2; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PTGS2; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; BCL2; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1; |
| NA: NA | Edema | NA | CA2; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | PTGS1; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1; FLT3; BCL2; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PIK3CA; |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; PTGS1; PTGS2; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | PTGS2; |
| NA: NA | Rheumatold arthritis | NA | PTGS1; PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1; |
| NA: NA | Miosis during ocular surgery | NA | PTGS1; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; IGF1R; |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; CA2; |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1; |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; BCL2; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | PTGS1; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; PTGS2; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PTGS2; |
| NA: NA | Gonorrheal vaginitis | NA | ESR1; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
| NA: NA | GIST | NA | FLT3; |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; PTGS2; |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; PTGS1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1; |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1; |
| NA: NA | Postmenopausal disorder | NA | ESR1; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
| NA: NA | Menopausal disorder | NA | ESR1; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | PIK3CB; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS1; PTGS2; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; ALPL; |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; PTGS1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; ACHE; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS1; PTGS2; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Amyotrophic lateral sclerosis | G12.2 | BCL2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; PTGS2; |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | BCL2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2; |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1; |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; |
| A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| C00-D49: Neoplasms | Advanced melanoma | C43 | BCL2; |
| NA: NA | Joint and muscular pain | NA | PTGS2; |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; CA9; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1; |
| C00-D49: Neoplasms | Cancer | C00-C96 | ESR1; PIM1; MET; CDK1; IGF1R; PIK3CA; KDR; NFKB1; FLT3; ACHE; PTGS2; PIK3CB; NQO2; CDC25B; CA9; BCL2; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
